

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascleris Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1672)

VOLUNTARY ANNOUNCEMENT

APPROVAL FOR MARKETING ALL-ORAL HCV TREATMENT

The Board of Directors (the “**Board**”) of Ascleris Pharma Inc. (the “**Company**”) is pleased to announce that, marketing for all-oral HCV treatment has been approved by National Medical Products Administration (國家藥品監督管理局, the NMPA).

Company’s all-oral HCV treatment is Ravidasvir (Asclevir®) in combination with Danoprevir (Ganovo®) (RDV/DNV Regimen).

Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % (SVR12) with a short treatment duration of 12 weeks in genotype 1 non-cirrhotic patients in China. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

Cautionary Statement required by Rule 18A.05 of the Listing Rules of the Hong Kong Stock Exchange: We cannot guarantee that we will be able to ultimately market the all-oral HCV treatment of Ravidasvir (Asclevir®) in combination with Danoprevir (Ganovo®) successfully.

By order of the Board
Ascleris Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People’s Republic of China
July 31, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.